INDIGO Biosciences launches calcitonin receptor reporter assay
INDIGO Biosciences has introduced a Human Calcitonin Receptor Reporter Assay to help drug developers measure receptor activity, potency and efficacy. The launch targets research in bone metabolism, obesity and other metabolic disorders, where calcitonin and amylin-related therapies are drawing more attention.
Why it matters: - The new assay gives researchers a functional tool to test calcitonin receptor activity in drug discovery programs. - The platform is designed to support work on bone metabolism, obesity and other metabolic disease programs tied to peptide therapeutics. - The launch expands INDIGO Biosciences' GPCR assay portfolio and adds a new option for teams studying calcitonin and amylin-related biology.
What happened: - INDIGO Biosciences announced the launch of its Human Calcitonin Receptor (CTR) Reporter Assay on November 12, 2026. - The company says the assay provides a cell-based platform for evaluating receptor activation, compound potency and efficacy. - The release positions the assay as a complement to INDIGO Biosciences' existing AMY1R and AMY3R Reporter Assays.
The details: - Calcitonin receptor is a class B GPCR involved in calcium regulation, bone metabolism and peptide hormone signaling. - CTR is activated primarily by calcitonin and helps regulate osteoclast activity and bone resorption. - The receptor is relevant to osteoporosis research, metabolic disorders and peptide-based therapeutics. - CTR forms the molecular foundation for three amylin receptors: AMY1, AMY2 and AMY3, when it associates with different receptor activity-modifying proteins, or RAMPs. - Those receptor complexes have overlapping but distinct pharmacological properties, which can complicate selective drug development. - The assay is built to generate concentration-response data. - It supports agonist screening, EC50 determination and comparative pharmacological characterization. - INDIGO Biosciences says the assay is especially useful for calcitonin analogs, amylin-related peptides and other candidates with overlapping receptor activity.
Between the lines: - Drug developers are paying closer attention to calcitonin receptor biology because amylin-related compounds and dual amylin and calcitonin receptor agonists, or DACRAs, are being explored for obesity and metabolic disease. - A functional assay like this can help researchers sort out receptor selectivity and potency earlier in development, where those questions can shape program direction. - The launch also signals continued demand for ready-to-use assay tools that shorten early-stage receptor pharmacology work.
What's next: - INDIGO Biosciences says the new assay is intended to support pharmaceutical and biotechnology companies pursuing receptor-targeted drug discovery. - The company is directing researchers to its website or direct contact for more information on applications and research support. - Further use of the assay will likely track broader interest in peptide therapeutics for bone and metabolic disease.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Pennsylvania Business Bulletin
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.